Immune-mediated haemolytic anaemia presenting post allogeneic bone marrow transplantation is often alloimmune in origin due to ABO or minor red cell incompatibilities. Autoimmune haemolytic anaemia is also recognised, is frequently difficult to treat and overall prognosis is often poor, usually from associated problems. Here, we present a case report of autoimmune haemolysis presenting in an 8-year-old boy 6 months post allogeneic bone marrow transplant requiring 4 years of immunosuppressive therapy before remission of haemolysis. This case report highlights the fact that it is possible for haemolysis to resolve post transplant even after years of immunosuppressive therapy. Bone Marrow Transplantation (2001) 28, 791-793.
Immune haemolytic anaemia following allogeneic bone marrow transplantation (BMT) is often alloimmune in origin. 1 Haemolysis of donor cells by recipient allo-antibodies can occur immediately if incompatible donor red cells are included in the graft or can be delayed and persistent due to residual recipient antibody production after the emergence of donor red cells post engraftment. This can continue for 6 to 12 months. Alloimmune haemolysis can also occur due to passive transfer of donor red cell antibodies at the time of stem cell infusion or with active production of donor red cell antibodies by engrafted donor lymphocytes. In contrast, haemolysis due to donor red cell antibodies is always short-lived.
Autoimmune haemolytic anaemia (AIHA) can also occur and may be associated with other cytopenias. [2] [3] [4] The incidence of autoimmune haemolytic anaemia in patients who have been allografted in two series was 3.1% 5 and 5% 6 although this may be an underestimate as mild haemolysis may go undetected. This incidence is much higher than Both cold-type and warm-type antibodies have been reported. Treatment of the haemolysis in these patients may be particularly difficult. Many patients die from associated problems such as graft-versus-host disease (GVHD) or sepsis but it is likely that immunosuppressive therapy required for the treatment of haemolysis may be partly contributory.
Here, we describe a patient with AIHA post allogeneic BMT requiring 4 years of immunosuppressive therapy, and we review the literature.
Case report
An 8-year-old boy presented in March 1995 with T cell acute lymphoblastic leukaemia with a haemoglobin 11 g/dl, white count of 289 × 10 9 /l, platelets 46 × 10 9 /l, hepatosplenomegaly and widespread lymphadenopathy. He was treated on the UKALL XI regimen 8 but had a CNS relapse in September 1995, entering a further remission on the relapse protocol. He underwent a matched unrelated bone marrow transplant on 23 February 1996 after conditioning with cranial irradiation, cyclophosphamide and total body irradiation. GVHD prophylaxis consisted of in vivo T cell depletion with Campath-1G and cyclosporin. Both donor and recipient were group O Rh(D) positive. He engrafted neutrophils to Ͼ0.5 × 10 9 /l by day 31 post transplant, requiring G-CSF, and had grade I GVHD affecting his skin only. In August 1998 he developed a pyrexial illness and a sore throat which was confirmed as infectious mononucleosis with a positive monospot test. By the end of August he was completely well, 6 months post transplant, with no evidence of chronic GVHD and immunosuppressive therapy was stopped. His FBC on 20 August 1996 was Hb 8.9 g/dl, WBC 3.5 × 10 9 /l, platelets 102 × 10 9 /l and his only medication was cotrimoxazole prophylaxis. On 18 September 1996 his FBC was Hb 4.0 g/dl, MCV 96, WBC 3.2, platelets 117. He was symptomatic of anaemia and examination revealed jaundice but no splenomegaly. His biochemistry confirmed hyperbilirubinaemia. The direct antiglobulin test was positive with red cells sensitised with both the IgG and the C3d components of complement. The antibody was a non-specific autoantibody active by the indirect antiglobulin technique and by enzyme techniques. An eluate prepared from the patient's cells also gave non-specific reactions by the indirect antiglobulin test. Heterogeneic absorption of the patients serum failed to identify any alloantibodies. Repeat red cell serology was performed in February 1997 confirming this result. His reticulocyte count was only 3.5% in September 1996 but increased to 6.8% by October 1996. Viral serology for CMV, parvovirus and mycoplasma were negative and the presence of IgG antibody to EBV was consistent with past infection. Abdominal ultrasound was normal. Bone marrow aspirate was consistent with haemolysis with a hypercellular marrow with increased erythropoiesis (normoblasts 49% of nucleated cells), left shifted erythropoiesis and slight dyserythropoiesis. A labelled red cell scan suggested that the spleen was not the site of destruction and showed a definite increase in liver activity consistent with hepatic sequestration. In view of this result splenectomy was not considered. He was initially given i.v. immunoglobulin (two doses of 15 g) and then started on 60 mg prednisolone (representing a dose of 2 mg/kg). He remained transfusion dependent, required anti-hypertensive therapy and became severely cushingnoid. In view of this, in November 1996 he was commenced on cyclosporin together with steroids but remained transfusion dependent. Subsequently, he was given i.v. cyclophosphamide (10 mg/kg) on five occasions from February to May 1997 and then commenced thalidomide in June 1997. After 8 weeks without transfusion the cyclosporin was stopped but a further attempt to reduce prednisolone was unsuccessful and thalidomide was gradually increased. He remained transfusion dependent and was started on weekly immunoglobulin (1 g/kg) in January 1998 together with slowly reducing steroids and thalidomide. Analysis of T cell recovery in January 1998 showed a moderate lymphopenia (0.92 × 10 9 /l) due mainly to a marked reduction in CD4 + T cells (0.07 × 10 9 /l). The immunoglobulin was stopped in August 1998. On this regimen he became transfusion independent for 7 months until his steroid dose reached 5 mg on alternate days when his haemoglobin fell again. It was not possible at this stage to wean him off steroids and thalidomide. In May 1999 he was given 5 days of anti-lymphocyte globulin (ALG). In July 1999 he was admitted to ICU with a fulminating head and neck bacterial infection from an initial parotitis. However, he became transfusion independent following the ALG and it was possible to slowly wean him off immunosuppressive medication. In February his prednisolone was reduced to 5 mg on alternate days and in August 2000 the thalidomide was stopped. He currently remains on thyroxine, testosterone and 5 mg prednisolone on alternate days as maintenance adrenal support.
Discussion
This case report illustrates that post transplant autoimmune haemolytic anaemia is a severe complication but that complete responses can occur even after years of immunosuppressive therapy. In this case a total of 4 years of immunosuppressive therapy was given before a complete response was attained. This consisted of continuous steroids and the following immunosuppressive treatments: cyclosporin, cyclophosphamide, thalidomide, intravenous immunoglobulin and anti-lymphocyte globulin. It is not clear whether immunosuppressive therapy altered the natural history of the disease or whether the haemolysis slowly resolved of its own accord. The onset of haemolysis coincided with the cessation of immunosuppressive therapy 6 months following transplantation and with an acute infection with EBV.
Although the exact mechanisms of post allogeneic BMT autoimmune haemolytic anaemia are poorly understood, post-transplant lymphoid regeneration is imperfect, predisposing to defective regulation of autoreactive B cells as a consequence of T cell defects and consequently an increase in autoimmune disorders. Hows et al 1 suggested that cyclosporin may dysregulate T cells and allow the development of autoantibodies as seen experimentally in murine syngeneic BMT. However, AIHA post allogeneic BMT has been reported in patients not receiving cyclosporin therapy 9 indicating that cyclosporin is not a prerequisite for the development of this syndrome. The commonest clinical associations with AIHA appear to be the development of GVHD 6, 8 and T cell depletion of the graft. 6 This probably reflects increased defective T cell function in the face of GVHD and T cell depletion. Our patient, while on thalidomide and prednisolone for almost 2 years post transplant, also had poor T cell reconstitution with a marked reduction in CD4
+ T cells (0.07 × 10 9 /l). CMV and disease relapse have also been reported in a few patients with onset of AIHA but it is not clear if these cases reflect coincidence rather than an association. 5 The study of Drobyski et al 6 described seven patients developing haemolysis a median of 10 months post allogeneic BMT (range 7-25 months). All seven patients had received T cell-depleted grafts. Five patients had partial or no response of their haemolysis to immunosuppressive therapy and four out of these five patients died, usually of sepsis (three of the four deaths). Only two of the seven patients had durable complete remissions from haemolysis following 16 and 18 months of steroid treatment. Splenectomy was of limited value in this study. Godder et al 10 reported five patients out of a series of 40 patients receiving partially mismatched bone marrow transplants who developed autoimmune haemolytic anaemia as the primary manifestation of chronic GVHD. This paper highlighted that AIHA is particularly prevalent after mismatched related transplants as a manifestation of cGVHD but in this setting appears to respond within a month to immunosuppressive treatment. The study of Chen et al 5 described nine patients with antired cell antibodies and clinically evident haemolysis or cold agglutination on blood film following allogeneic transplantation. This study identified two groups: a group with a warm autoantibody manifesting after 6 months post transplant and a group with a cold autoantibody presenting earlier than this. Haemolysis was associated with the onset of GVHD in three cases (3/9) all with a cold AIHA, with the onset of CMV infection in four cases (4/9) and with cytogenetic relapse of CML in three cases (3/9). Again, this study showed that warm-type autoantibodies associated with haemolysis are difficult to treat. Of the five with warm AIHA, three eventually responded to immunosuppressive therapy, namely prednisolone and immunoglobulin, prednisolone and splenectomy and prednisolone, azathioprine, splenectomy, total lymphoid irradiation, respectively.
In summary, our case report highlights that AIHA post allogeneic BMT is a clinically significant complication and the overall response to therapy is generally unsatisfactory. However, haemolysis did resolve after 4 years of continuing immunosuppressive therapy indicating that patients who survive long enough can eventually resolve their haemolysis.
